{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T01:24:00Z","timestamp":1782955440953,"version":"3.54.5"},"reference-count":241,"publisher":"Bentham Science Publishers Ltd.","issue":"33","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Parkinson\u2019s disease (PD) is the second most common neurodegenerative disorder worldwide. The symptoms of PD are characterized not only by motor alterations but also by a spectrum of nonmotor symptoms. Some of these are psychiatric manifestations such as sleep disorders; depression; cognitive difficulties that can evolve into dementia; and symptoms of psychosis, which include hallucinations, illusions, and delusions. Parkinson\u2019s disease psychosis (PDP) occurs in 18%\u201350% of patients with PD. Treating PDP is challenging because antipsychotic drugs tend to be inefficient or may even worsen the motor symptoms of the disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>This is a narrative review in which an extensive literature search was performed on the Scopus, EMBASE, PubMed, ISI Web of Science, and Google Scholar databases, from inception to August 2021. The terms \u201cParkinson\u2019s disease psychosis,\u201d \u201cParkinson psychosis,\u201d \u201cneurodegenerative psychosis,\u201d and \u201cdopamine psychosis\u201d were among the keywords used in the search.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>current understanding of the molecular mechanisms involved in PDP, as well as recent innovative alternatives for its treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Recently, views on the etiology of hallucinations and illusions have evolved remarkably. PDP has been cemented as a multifactorial entity that is dependent not only on extrinsic mechanisms but also novel intrinsic mechanisms including genetic factors, neurostructural alterations, functional disruptions, visual processing disturbances, and sleep disorders. Consequently, innovative pharmacological and biological treatments have been proposed. Pimavanserin, a selective 5-HT2A inverse agonist, stands out after its approval for the treatment of PDP-associated hallucinations and illusions.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Future results from upcoming clinical trials should further characterize the role of this drug in the management of PDP as well as other treatment options with novel mechanisms of action, such as saracatinib, SEP-363856, cannabidiol, electroconvulsive therapy, and transcranial magnetic stimulation.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612828666220428102802","type":"journal-article","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T15:08:32Z","timestamp":1651331312000},"page":"2725-2741","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Psychosis in Parkinson\u2019s Disease: Looking Beyond Dopaminergic Treatments"],"prefix":"10.2174","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2764-8846","authenticated-orcid":true,"given":"Milagros","family":"Rojas","sequence":"first","affiliation":[{"name":"Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, 4004 Maracaibo, Venezuela"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8511-0230","authenticated-orcid":true,"given":"Mervin","family":"Ch\u00e1vez-Castillo","sequence":"additional","affiliation":[{"name":"Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, 4004 Maracaibo, Venezuela"},{"name":"Psychiatric Hospital of Maracaibo, Maracaibo, Venezuela"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8030-1780","authenticated-orcid":true,"given":"Pablo","family":"Duran","sequence":"additional","affiliation":[{"name":"Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, 4004 Maracaibo, Venezuela"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7180-4765","authenticated-orcid":true,"given":"\u00c1ngel","family":"Ortega","sequence":"additional","affiliation":[{"name":"Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, 4004 Maracaibo, Venezuela"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6259-2812","authenticated-orcid":true,"given":"Mar\u00eda Judith","family":"Bautista-Sandoval","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias Jur\u00eddicas y Sociales, Universidad Sim\u00f3n Bol\u00edvar,\nC\u00facuta 540006, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4211-528X","authenticated-orcid":true,"given":"Juan","family":"Salazar","sequence":"additional","affiliation":[{"name":"Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, 4004 Maracaibo, Venezuela"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4476-9538","authenticated-orcid":true,"given":"Manuel","family":"Ria\u00f1o-Garz\u00f3n","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias Jur\u00eddicas y Sociales, Universidad Sim\u00f3n Bol\u00edvar,\nC\u00facuta 540006, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5208-9401","authenticated-orcid":true,"given":"Maricarmen","family":"Chac\u00edn","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias de la Salud, Universidad Sim\u00f3n Bol\u00edvar, Barranquilla 080002, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2472-1238","authenticated-orcid":true,"given":"Oscar","family":"Medina-Ortiz","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias Jur\u00eddicas y Sociales, Universidad Sim\u00f3n Bol\u00edvar,\nC\u00facuta 540006, Colombia"},{"name":"Facultad de Medicina, Universidad de Santander, C\u00facuta, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8582-2155","authenticated-orcid":true,"given":"Jim","family":"Palmar","sequence":"additional","affiliation":[{"name":"Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, 4004 Maracaibo, Venezuela"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3120-4757","authenticated-orcid":true,"given":"Lorena","family":"Cudris-Torres","sequence":"additional","affiliation":[{"name":"Programa de Psicolog\u00eda, Fundaci\u00f3n Universitaria del \u00c1rea\nAndina, Valledupar 200001, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1880-8887","authenticated-orcid":true,"given":"Valmore","family":"Berm\u00fadez","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias Jur\u00eddicas y Sociales, Universidad Sim\u00f3n Bol\u00edvar,\nC\u00facuta 540006, Colombia"},{"name":"Facultad de Ciencias de la Salud, Universidad Sim\u00f3n Bol\u00edvar, Barranquilla 080002, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41531-018-0058-0","volume":"4","author":"Marras C.","year":"2018","unstructured":"Marras C.; Beck J.C.; Bower J.H.; Prevalence of Parkinson\u2019s disease across North America. NPJ Parkinsons Dis 2018,4(1),21","journal-title":"NPJ Parkinsons Dis"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"Dorsey E.R.","year":"2018","unstructured":"Dorsey E.R.; Elbaz A.; Nichols E.; Global, regional, and national burden of Parkinson\u2019s disease, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018,17(11),939-953","journal-title":"Lancet Neurol"},{"key":"ref=3","unstructured":"The economic burden of Parkinson\u2019s Disease Michael J Fox Foundation for Parkinson\u2019s Research Lewin GroupAvailable from:  (Accessed on 2021 Jul 18).","journal-title":"The economic burden of Parkinson\u2019s Disease Michael J Fox Foundation for Parkinson\u2019s Research"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"Jankovic J.","year":"2008","unstructured":"Jankovic J.; Parkinson\u2019s disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008,79(4),368-376","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s10020-021-00301-7","volume":"27","author":"Hirano S.","year":"2021","unstructured":"Hirano S.; Clinical implications for dopaminergic and functional neuroimage research in cognitive symptoms of Parkinson\u2019s disease. Mol Med 2021,27(1),40","journal-title":"Mol Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12955-021-01740-w","volume":"19","author":"He Y.","year":"2021","unstructured":"He Y.; Tian Y.; Han H.; The path linking disease severity and cognitive function with quality of life in Parkinson\u2019s disease: The mediating effect of activities of daily living and depression. Health Qual Life Outcomes 2021,19(1),92","journal-title":"Health Qual Life Outcomes"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1468-1331.2008.02056.x","volume":"15","author":"Poewe W.","year":"2008","unstructured":"Poewe W.; Non-motor symptoms in Parkinson\u2019s disease. Eur J Neurol 2008,15(S1),14-20","journal-title":"Eur J Neurol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/archneurol.2010.166","volume":"67","author":"Forsaa E.B.","year":"2010","unstructured":"Forsaa E.B.; Larsen J.P.; Wentzel-Larsen T.; A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol 2010,67(8),996-1001","journal-title":"Arch Neurol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mds.10374","volume":"18","author":"Fernandez H.H.","year":"2003","unstructured":"Fernandez H.H.; Trieschmann M.E.; Burke M.A.; Jacques C.; Friedman J.H.; Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 2003,18(5),510-514","journal-title":"Mov Disord"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"4938154","DOI":"10.1155\/2016\/4938154","volume":"2016","author":"Divac N.","year":"2016","unstructured":"Divac N.; Stojanovi\u0107 R.; Vujovi\u0107 SK; Medi\u0107 B; Damjanovi\u0107 A; Prostran M; The efficacy and safety of antipsychotic medications in the treatment of psychosis in patients with parkinson\u2019s disease. Behav Neurol 2016,2016,4938154","journal-title":"Behav Neurol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1192\/bjpo.bp.115.000927","volume":"1","author":"Jethwa K.D.","year":"2015","unstructured":"Jethwa K.D.; Onalaja O.A.; Antipsychotics for the management of psychosis in Parkinson\u2019s disease: Systematic review and meta-analysis. BJPsych Open 2015,1(1),27-33","journal-title":"BJPsych Open"},{"key":"ref=12","first-page":"25","volume":"17","author":"G\u00f3mez-Chavar\u00edn M.","year":"2012","unstructured":"G\u00f3mez-Chavar\u00edn M.; Roldan-Roldan G.; Morales-Espinosa R.; P\u00e9rez-Soto G.; Torner-Aguilar C.; Mecanismos fisiopatol\u00f3gicos involucrados en la enfermedad de Parkinson. Arch Neurocienc 2012,17(1),25-33","journal-title":"Arch Neurocienc"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/mdc3.12550","volume":"5","author":"Hinkle J.T.","year":"2018","unstructured":"Hinkle J.T.; Perepezko K.; Bakker C.C.; Onset and remission of psychosis in parkinson\u2019s disease: Pharmacologic and motoric markers. Mov Disord Clin Pract (Hoboken) 2018,5(1),31-38","journal-title":"Mov Disord Clin Pract (Hoboken)"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"3256542","DOI":"10.1155\/2017\/3256542","volume":"2017","author":"Taddei R.N.","year":"2017","unstructured":"Taddei R.N.; Cankaya S.; Dhaliwal S.; Chaudhuri K.R.; Management of psychosis in Parkinson\u2019s disease: Emphasizing clinical subtypes and pathophysiological mechanisms of the condition. Park Dis 2017,2017,3256542","journal-title":"Park Dis"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1002\/mds.10140","volume":"17","author":"Bergman H.","year":"2002","unstructured":"Bergman H.; Deuschl G.; Pathophysiology of Parkinson\u2019s disease: From clinical neurology to basic neuroscience and back. Mov Disord 2002,17(S3),S28-S40","journal-title":"Mov Disord"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJM198804073181402","volume":"318","author":"Kish S.J.","year":"1988","unstructured":"Kish S.J.; Shannak K.; Hornykiewicz O.; Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson\u2019s disease. Pathophysiologic and clinical implications. N Engl J Med 1988,318(14),876-880","journal-title":"N Engl J Med"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.expneurol.2017.10.002","volume":"298","author":"Blesa J","year":"2017","unstructured":"Blesa J; Trigo-Damas I; Dileone M; Del Rey NL-G; Hernandez LF; Obeso JA; Compensatory mechanisms in Parkinson\u2019s disease: Circuits adaptations and role in disease modification. Exp Neurol 2017,298((Pt B)),148-161","journal-title":"Exp Neurol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/mds.26579","volume":"31","author":"Navntoft C.A.","year":"2016","unstructured":"Navntoft C.A.; Dreyer J.K.; How compensation breaks down in Parkinson\u2019s disease: Insights from modeling of denervated striatum. Mov Disord 2016,31(3),280-289","journal-title":"Mov Disord"},{"key":"ref=19","first-page":"567","volume":"54","author":"Antkiewicz-Michaluk L.","year":"2002","unstructured":"Antkiewicz-Michaluk L.; Endogenous risk factors in Parkinson\u2019s disease: Dopamine and tetrahydroisoquinolines. Pol J Pharmacol 2002,54(6),567-572","journal-title":"Pol J Pharmacol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3389\/fnins.2018.00612","volume":"12","author":"Emamzadeh F.N.","year":"2018","unstructured":"Emamzadeh F.N.; Surguchov A.; Parkinson\u2019s disease: Biomarkers, treatment, and risk factors. Front Neurosci 2018,12,612","journal-title":"Front Neurosci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0165-0173(94)00007-C","volume":"20","author":"Parent A.","year":"1995","unstructured":"Parent A.; Hazrati L.N.; Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev 1995,20(1),91-127","journal-title":"Brain Res Brain Res Rev"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.neurol.2008.04.019","volume":"164","author":"Yelnik J.","year":"2008","unstructured":"Yelnik J.; Modeling the organization of the basal ganglia. Rev Neurol (Paris) 2008,164(12),969-976","journal-title":"Rev Neurol (Paris)"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/bph.12906","volume":"172","author":"Beaulieu J-M.","year":"2015","unstructured":"Beaulieu J-M.; Espinoza S.; Gainetdinov R.R.; Dopamine receptors - IUPHAR Review 13. Br J Pharmacol 2015,172(1),1-23","journal-title":"Br J Pharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","volume":"78","author":"Missale C.","year":"1998","unstructured":"Missale C.; Nash S.R.; Robinson S.W.; Jaber M.; Caron M.G.; Dopamine receptors: From structure to function. Physiol Rev 1998,78(1),189-225","journal-title":"Physiol Rev"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1016\/S1471-1931(00)00019-7","volume":"23","author":"Gerfen C.R.","year":"2000","unstructured":"Gerfen C.R.; Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci 2000,23(10),S64-S70","journal-title":"Trends Neurosci"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2174\/187152706784111551","volume":"5","author":"Sokoloff P.","year":"2006","unstructured":"Sokoloff P.; Diaz J.; Le Foll B.; The dopamine D3 receptor: A therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006,5(1),25-43","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1124\/pr.110.002642","volume":"63","author":"Beaulieu J-M.","year":"2011","unstructured":"Beaulieu J-M.; Gainetdinov R.R.; The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011,63(1),182-217","journal-title":"Pharmacol Rev"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0306-4522(02)00067-2","volume":"112","author":"Joseph J.D.","year":"2002","unstructured":"Joseph J.D.; Wang Y-M.; Miles P.R.; Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D(3) receptors. Neuroscience 2002,112(1),39-49","journal-title":"Neuroscience"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0165-6147(92)90025-2","volume":"13","author":"Sibley D.R.","year":"1992","unstructured":"Sibley D.R.; Monsma F.J.; Molecular biology of dopamine receptors. Trends Pharmacol Sci 1992,13(2),61-69","journal-title":"Trends Pharmacol Sci"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"S548","DOI":"10.1002\/mds.22062","volume":"23","author":"Obeso J.A.","year":"2008","unstructured":"Obeso J.A.; Rodr\u00edguez-Oroz M.C.; Benitez-Temino B.; Functional organization of the basal ganglia: Therapeutic implications for Parkinson\u2019s disease. Mov Disord 2008,23(S3),S548-S559","journal-title":"Mov Disord"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"18531","DOI":"10.1523\/JNEUROSCI.1278-13.2013","volume":"33","author":"Freeze B.S.","year":"2013","unstructured":"Freeze B.S.; Kravitz A.V.; Hammack N.; Berke J.D.; Kreitzer A.C.; Control of basal ganglia output by direct and indirect pathway projection neurons. J Neurosci 2013,33(47),18531-18539","journal-title":"J Neurosci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fncel.2011.00007","volume":"5","author":"Shrivastava A.N.","year":"2011","unstructured":"Shrivastava A.N.; Triller A.; Sieghart W.; GABA(A) Receptors: Post-Synaptic Co-localization and cross-talk with other receptors. Front Cell Neurosci 2011,5,7","journal-title":"Front Cell Neurosci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fnana.2015.00005","volume":"9","author":"Galvan A.","year":"2015","unstructured":"Galvan A.; Devergnas A.; Wichmann T.; Alterations in neuronal activity in basal ganglia-thalamocortical circuits in the Parkinsonian state. Front Neuroanat 2015,9,5","journal-title":"Front Neuroanat"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.arr.2014.01.004","volume":"14","author":"Reeve A.","year":"2014","unstructured":"Reeve A.; Simcox E.; Turnbull D.; Ageing and Parkinson\u2019s disease: Why is advancing age the biggest risk factor? Ageing Res Rev 2014,14,19-30","journal-title":"Ageing Res Rev"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1093\/aje\/kwq303","volume":"172","author":"Willis A.W.","year":"2010","unstructured":"Willis A.W.; Evanoff B.A.; Lian M.; Metal emissions and urban incident Parkinson disease: A community health study of Medicare beneficiaries by using geographic information systems. Am J Epidemiol 2010,172(12),1357-1363","journal-title":"Am J Epidemiol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1136\/oem.2006.027003","volume":"64","author":"Dick F.D.","year":"2007","unstructured":"Dick F.D.; De Palma G.; Ahmadi A.; Environmental risk factors for Parkinson\u2019s disease and parkinsonism: The Geoparkinson study. Occup Environ Med 2007,64(10),666-672","journal-title":"Occup Environ Med"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.pneurobio.2013.04.004","volume":"106-107","author":"Subramaniam S.R.","year":"2013","unstructured":"Subramaniam S.R.; Chesselet M-F.; Mitochondrial dysfunction and oxidative stress in Parkinson\u2019s disease. Prog Neurobiol 2013,106-107,17-32","journal-title":"Prog Neurobiol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3389\/fncel.2018.00247","volume":"12","author":"Ferreira S.A.","year":"2018","unstructured":"Ferreira S.A.; Romero-Ramos M.; Microglia response during parkinson\u2019s disease: Alpha-synuclein intervention. Front Cell Neurosci 2018,12,247","journal-title":"Front Cell Neurosci"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3389\/fnmol.2014.00063","volume":"7","author":"Atkin G.","year":"2014","unstructured":"Atkin G.; Paulson H.; Ubiquitin pathways in neurodegenerative disease. Front Mol Neurosci 2014,7,63","journal-title":"Front Mol Neurosci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/mds.26243","volume":"30","author":"Park J-S.","year":"2015","unstructured":"Park J-S.; Blair N.F.; Sue C.M.; The role of ATP13A2 in Parkinson\u2019s disease: Clinical phenotypes and molecular mechanisms. Mov Disord 2015,30(6),770-779","journal-title":"Mov Disord"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/gm566","volume":"6","author":"Lin M.K.","year":"2014","unstructured":"Lin M.K.; Farrer M.J.; Genetics and genomics of Parkinson\u2019s disease. Genome Med 2014,6(6),48","journal-title":"Genome Med"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"a008888","DOI":"10.1101\/cshperspect.a008888","volume":"2","author":"Klein C.","year":"2012","unstructured":"Klein C.; Westenberger A.; Genetics of Parkinson\u2019s disease. Cold Spring Harb Perspect Med 2012,2(1),a008888","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12035-012-8280-y","volume":"47","author":"Wakabayashi K.","year":"2013","unstructured":"Wakabayashi K.; Tanji K.; Odagiri S.; Miki Y.; Mori F.; Takahashi H.; The Lewy body in Parkinson\u2019s disease and related neurodegenerative disorders. Mol Neurobiol 2013,47(2),495-508","journal-title":"Mol Neurobiol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1073\/pnas.0509567103","volume":"103","author":"Shults C.W.","year":"2006","unstructured":"Shults C.W.; Lewy bodies. Proc Natl Acad Sci USA 2006,103(6),1661-1668","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/j.1440-1789.2007.00803.x","volume":"27","author":"Wakabayashi K.","year":"2007","unstructured":"Wakabayashi K.; Tanji K.; Mori F.; Takahashi H.; The Lewy body in Parkinson\u2019s disease: Molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 2007,27(5),494-506","journal-title":"Neuropathology"},{"key":"ref=46","first-page":"615","volume":"125","author":"Jellinger KA","year":"2018","unstructured":"Jellinger KA; Dementia with Lewy bodies and Parkinson\u2019s disease-dementia: Current concepts and controversies. J Neural Transm Vienna Austria 1996 2018,125(4),615-650","journal-title":"J Neural Transm Vienna Austria 1996"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12916-018-1016-8","volume":"16","author":"Jellinger K.A.","year":"2018","unstructured":"Jellinger K.A.; Korczyn A.D.; Are dementia with Lewy bodies and Parkinson\u2019s disease dementia the same disease? BMC Med 2018,16(1),34","journal-title":"BMC Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1471-2202-14-65","volume":"14","author":"Sogabe S.","year":"2013","unstructured":"Sogabe S.; Yagasaki Y.; Onozawa K.; Kawakami Y.; Mesocortical dopamine system modulates mechanical nociceptive responses recorded in the rat prefrontal cortex. BMC Neurosci 2013,14(1),65","journal-title":"BMC Neurosci"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1755-7682-3-24","volume":"3","author":"Arias-Carri\u00f3n O.","year":"2010","unstructured":"Arias-Carri\u00f3n O.; Stamelou M.; Murillo-Rodr\u00edguez E.; Men\u00e9ndez-Gonz\u00e1lez M.; P\u00f6ppel E.; Dopaminergic reward system: A short integrative review. Int Arch Med 2010,3(1),24","journal-title":"Int Arch Med"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1210\/edrv.22.6.0451","volume":"22","author":"Ben-Jonathan N.","year":"2001","unstructured":"Ben-Jonathan N.; Hnasko R.; Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001,22(6),724-763","journal-title":"Endocr Rev"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/ADM.0b013e31819a86f7","volume":"3","author":"Wang G-J.","year":"2009","unstructured":"Wang G-J.; Volkow N.D.; Thanos P.K.; Fowler J.S.; Imaging of brain dopamine pathways: Implications for understanding obesity. J Addict Med 2009,3(1),8-18","journal-title":"J Addict Med"},{"key":"ref=52","first-page":"93","volume":"3","author":"Tarazi F.I.","year":"2001","unstructured":"Tarazi F.I.; Neuropharmacology of dopamine receptors: Implications in neuropsychiatric diseases. J Sci Res Med Sci 2001,3(2),93-104","journal-title":"J Sci Res Med Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/ijnp\/pyx056","volume":"20","author":"Belujon P.","year":"2017","unstructured":"Belujon P.; Grace A.A.; Dopamine system dysregulation in major depressive disorders. Int J Neuropsychopharmacol 2017,20(12),1036-1046","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"893","DOI":"10.4067\/S0034-98872006000700014","volume":"134","author":"Juri C.C.","year":"2006","unstructured":"Juri C.C.; Chan\u00e1 C.P.; Levodopa for Parkinson\u2019s disease: What have we learned? Rev Med Chil 2006,134(7),893-901","journal-title":"Rev Med Chil"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"16005","DOI":"10.1038\/s41598-017-16228-1","volume":"7","author":"Lerner R.P.","year":"2017","unstructured":"Lerner R.P.; Francardo V.; Fujita K.; Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia. Sci Rep 2017,7(1),16005","journal-title":"Sci Rep"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2174\/138920021705160324170558","volume":"17","author":"Montioli R.","year":"2016","unstructured":"Montioli R.; Voltattorni C.B.; Bertoldi M.; Parkinson\u2019s disease: Recent updates in the identification of human dopa decarboxylase inhibitors. Curr Drug Metab 2016,17(5),513-518","journal-title":"Curr Drug Metab"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"349","DOI":"10.14336\/AD.2015.0330","volume":"6","author":"Rangel-Barajas C.","year":"2015","unstructured":"Rangel-Barajas C.; Coronel I.; Flor\u00e1n B.; Dopamine receptors and neurodegeneration. Aging Dis 2015,6(5),349-368","journal-title":"Aging Dis"},{"key":"ref=58","first-page":"37","volume":"89","author":"Borovac J.A.","year":"2016","unstructured":"Borovac J.A.; Side effects of a dopamine agonist therapy for Parkinson\u2019s disease: A mini-review of clinical pharmacology. Yale J Biol Med 2016,89(1),37-47","journal-title":"Yale J Biol Med"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/mds.23590","volume":"26","author":"Sampaio C.","year":"2011","unstructured":"Sampaio C.; Bronzova J.; Hauser R.A.; Pardoprunox in early Parkinson\u2019s disease: Results from 2 large, randomized double-blind trials. Mov Disord 2011,26(8),1464-1476","journal-title":"Mov Disord"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2741\/S415","volume":"6","author":"Beitz J.M.","year":"2014","unstructured":"Beitz J.M.; Parkinson\u2019s disease: A review. Front Biosci Sch Ed 2014,6,65-74","journal-title":"Front Biosci Sch Ed"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.clinthera.2006.08.004","volume":"28","author":"Kvernmo T.","year":"2006","unstructured":"Kvernmo T.; H\u00e4rtter S.; Burger E.; A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006,28(8),1065-1078","journal-title":"Clin Ther"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.nrl.2011.04.012","volume":"29","author":"C\u00e1novas A.A.","year":"2014","unstructured":"C\u00e1novas A.A.; Piudo L.R.; Ruiz-Espiga G.P.; Dopaminergic agonists in Parkinson\u2019s disease. Neurologia 2014,29(4),230-241","journal-title":"Neurologia"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1212\/01.WNL.0000134672.44217.F7","volume":"63","author":"Stocchi F.","year":"2004","unstructured":"Stocchi F.; Arnold G.; Onofrj M.; Improvement of motor function in early Parkinson disease by safinamide. Neurology 2004,63(4),746-748","journal-title":"Neurology"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1478-811X-11-34","volume":"11","author":"Meiser J.","year":"2013","unstructured":"Meiser J.; Weindl D.; Hiller K.; Complexity of dopamine metabolism. Cell Commun Signal 2013,11(1),34","journal-title":"Cell Commun Signal"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"Connolly B.S.","year":"2014","unstructured":"Connolly B.S.; Lang A.E.; Pharmacological treatment of Parkinson disease: A review. JAMA 2014,311(16),1670-1683","journal-title":"JAMA"},{"key":"ref=66","first-page":"1359","volume":"117","author":"Korchounov A","year":"2010","unstructured":"Korchounov A; Meyer MF; Krasnianski M; Postsynaptic nigrostriatal dopamine receptors and their role in movement regulation. J Neural Transm Vienna Austria 1996 2010,117(12),1359-1369","journal-title":"J Neural Transm Vienna Austria 1996"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.nrl.2010.09.007","volume":"26","author":"\u00c1vila A.","year":"2011","unstructured":"\u00c1vila A.; Cardona X.; Bello J.; Maho P.; Sastre F.; Mart\u00edn-Baranera M.; Impulse control disorders and punding in Parkinson's disease: The need for a structured interview. Neurologia 2011,26(3),166-172","journal-title":"Neurologia"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/NRL.0b013e3181883dd4","volume":"15","author":"Cannas A.","year":"2009","unstructured":"Cannas A.; Solla P.; Floris G.; Tacconi P.; Marrosu F.; Marrosu M.G.; Othello syndrome in Parkinson disease patients without dementia. Neurologist 2009,15(1),34-36","journal-title":"Neurologist"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/mds.20464","volume":"20","author":"Goetz C.G.","year":"2005","unstructured":"Goetz C.G.; Poewe W.; Rascol O.; Sampaio C.; Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson\u2019s disease: 2001 to 2004. Mov Disord 2005,20(5),523-539","journal-title":"Mov Disord"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/mds.23034","volume":"25","author":"Wolf E.","year":"2010","unstructured":"Wolf E.; Seppi K.; Katzenschlager R.; Long-term antidyskinetic efficacy of amantadine in Parkinson\u2019s disease. Mov Disord 2010,25(10),1357-1363","journal-title":"Mov Disord"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/1471-2377-13-145","volume":"13","author":"Sawada H.","year":"2013","unstructured":"Sawada H.; Oeda T.; Yamamoto K.; Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: A retrospective cohort study. BMC Neurol 2013,13(1),145","journal-title":"BMC Neurol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1471-2377-9-23","volume":"9","author":"Ecker D.","year":"2009","unstructured":"Ecker D.; Unrath A.; Kassubek J.; Sabolek M.; Dopamine Agonists and their risk to induce psychotic episodes in Parkinson\u2019s disease: A case-control study. BMC Neurol 2009,9(1),23","journal-title":"BMC Neurol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"CD006564","DOI":"10.1002\/14651858.CD006564.pub2","author":"Stowe R.L.","year":"2008","unstructured":"Stowe R.L.; Ives N.J.; Clarke C.; Dopamine agonist therapy in early Parkinson\u2019s disease. Cochrane Database Syst Rev 2008(2),CD006564","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/2047-9158-1-10","volume":"1","author":"M\u00fcller T.","year":"2012","unstructured":"M\u00fcller T.; Drug therapy in patients with Parkinson\u2019s disease. Transl Neurodegener 2012,1(1),10","journal-title":"Transl Neurodegener"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2147\/NDT.S101569","volume":"12","author":"Xu W-J.","year":"2016","unstructured":"Xu W-J.; Wei N.; Xu Y.; Hu S-H.; Does amantadine induce acute psychosis? A case report and literature review. Neuropsychiatr Dis Treat 2016,12,781-783","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1517\/14656566.2011.587122","volume":"12","author":"Goldman J.G.","year":"2011","unstructured":"Goldman J.G.; Vaughan C.L.; Goetz C.G.; An update expert opinion on management and research strategies in Parkinson\u2019s disease psychosis. Expert Opin Pharmacother 2011,12(13),2009-2024","journal-title":"Expert Opin Pharmacother"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1017\/S1092852900017296","volume":"13","author":"Zahodne L.B.","year":"2008","unstructured":"Zahodne L.B.; Fernandez H.H.; Course, prognosis, and management of psychosis in Parkinson\u2019s disease: Are current treatments really effective? CNS Spectr 2008,13(3)(Suppl. 4),26-33","journal-title":"CNS Spectr"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.4103\/0972-2327.83090","volume":"14","year":"2011","unstructured":"Ann Indian Acad Neurol Psychosis in Parkinson\u2019s disease2011,14(Suppl. 1),S16-S17","journal-title":"Ann Indian Acad Neurol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/npp.2011.278","volume":"37","author":"Nagy H.","year":"2012","unstructured":"Nagy H.; Levy-Gigi E.; Somlai Z.; Tak\u00e1ts A.; Bereczki D.; K\u00e9ri S.; The effect of dopamine agonists on adaptive and aberrant salience in Parkinson\u2019s disease. Neuropsychopharmacology 2012,37(4),950-958","journal-title":"Neuropsychopharmacology"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1212\/WNL.0000000000000801","volume":"83","author":"de la Riva P.","year":"2014","unstructured":"de la Riva P.; Smith K.; Xie S.X.; Weintraub D.; Course of psychiatric symptoms and global cognition in early Parkinson disease. Neurology 2014,83(12),1096-1103","journal-title":"Neurology"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1176\/ajp.135.6.669","volume":"135","author":"Moskovitz C.","year":"1978","unstructured":"Moskovitz C.; Moses H.; Klawans H.L.; Levodopa-induced psychosis: A kindling phenomenon. Am J Psychiatry 1978,135(6),669-675","journal-title":"Am J Psychiatry"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.bbr.2009.12.048","volume":"221","author":"Bohnen N.I.","year":"2011","unstructured":"Bohnen N.I.; Albin R.L.; The cholinergic system and Parkinson disease. Behav Brain Res 2011,221(2),564-573","journal-title":"Behav Brain Res"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s40265-016-0600-5","volume":"76","author":"Chang A.","year":"2016","unstructured":"Chang A.; Fox S.H.; Psychosis in Parkinson\u2019s disease: Epidemiology, Pathophysiology, and Management. Drugs 2016,76(11),1093-1118","journal-title":"Drugs"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/toxics3010075","volume":"3","author":"Stansley B.J.","year":"2015","unstructured":"Stansley B.J.; Yamamoto B.K.; L-dopa and brain serotonin system dysfunction. Toxics 2015,3(1),75-88","journal-title":"Toxics"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"III22","DOI":"10.1007\/PL00007822","volume":"248","author":"Wolters E.C.","year":"2001","unstructured":"Wolters E.C.; Intrinsic and extrinsic psychosis in Parkinson\u2019s disease. J Neurol 2001,248(S3),III22-III27","journal-title":"J Neurol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1136\/jnnp-2011-300043","volume":"83","author":"Morgante L.","year":"2012","unstructured":"Morgante L.; Colosimo C.; Antonini A.; Psychosis associated to Parkinson\u2019s disease in the early stages: Relevance of cognitive decline and depression. J Neurol Neurosurg Psychiatry 2012,83(1),76-82","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1212\/WNL.50.2.515","volume":"50","author":"Goetz C.G.","year":"1998","unstructured":"Goetz C.G.; Pappert E.J.; Blasucci L.M.; Intravenous levodopa in hallucinating Parkinson\u2019s disease patients: High-dose challenge does not precipitate hallucinations. Neurology 1998,50(2),515-517","journal-title":"Neurology"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.parkreldis.2008.11.013","volume":"15","author":"Dotchin C.L.","year":"2009","unstructured":"Dotchin C.L.; Jusabani A.; Walker R.W.; Non-motor symptoms in a prevalent population with Parkinson\u2019s disease in Tanzania. Parkinsonism Relat Disord 2009,15(6),457-460","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/mds.26432","volume":"31","author":"Pagonabarraga J.","year":"2016","unstructured":"Pagonabarraga J.; Martinez-Horta S.; Fern\u00e1ndez de Bobadilla R.; Minor hallucinations occur in drug-naive Parkinson\u2019s disease patients, even from the premotor phase. Mov Disord 2016,31(1),45-52","journal-title":"Mov Disord"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/2152-7806.106265","volume":"4","author":"Widge A.S.","year":"2013","unstructured":"Widge A.S.; Agarwal P.; Giroux M.; Farris S.; Kimmel R.J.; Hebb A.O.; Psychosis from subthalamic nucleus deep brain stimulator lesion effect. Surg Neurol Int 2013,4(1),7","journal-title":"Surg Neurol Int"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s13311-014-0274-1","volume":"11","author":"Larson P.S.","year":"2014","unstructured":"Larson P.S.; Deep brain stimulation for movement disorders. Neurother J Am Soc Exp Neurother 2014,11(3),465-474","journal-title":"Neurother J Am Soc Exp Neurother"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3389\/fnins.2016.00173","volume":"10","author":"Hickey P.","year":"2016","unstructured":"Hickey P.; Stacy M.; Deep brain stimulation: a paradigm shifting approach to treat parkinson\u2019s disease. Front Neurosci 2016,10,173","journal-title":"Front Neurosci"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.1002\/mds.10162","volume":"17","author":"Volkmann J.","year":"2002","unstructured":"Volkmann J.; Herzog J.; Kopper F.; Deuschl G.; Introduction to the programming of deep brain stimulators. Mov Disord 2002,17(S3),S181-S187","journal-title":"Mov Disord"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.3171\/2015.3.FOCUS1523","volume":"38","author":"Qureshi A.A.","year":"2015","unstructured":"Qureshi A.A.; Cheng J.J.; Sunshine A.N.; Postoperative symptoms of psychosis after deep brain stimulation in patients with Parkinson\u2019s disease. Neurosurg Focus 2015,38(6),E5","journal-title":"Neurosurg Focus"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1212\/01.WNL.0000161872.85903.8E","volume":"64","author":"Paleacu D.","year":"2005","unstructured":"Paleacu D.; Schechtman E.; Inzelberg R.; Association between family history of dementia and hallucinations in Parkinson disease. Neurology 2005,64(10),1712-1715","journal-title":"Neurology"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1600-0404.2005.00535.x","volume":"113","author":"Feldman B.","year":"2006","unstructured":"Feldman B.; Chapman J.; Korczyn A.D.; Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson\u2019s disease. Acta Neurol Scand 2006,113(1),14-17","journal-title":"Acta Neurol Scand"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3233\/JAD-2011-110356","volume":"26","author":"Alexopoulos P.","year":"2011","unstructured":"Alexopoulos P.; Richter-Schmidinger T.; Horn M.; Hippocampal volume differences between healthy young apolipoprotein E \u03b52 and \u03b54 carriers. J Alzheimers Dis 2011,26(2),207-210","journal-title":"J Alzheimers Dis"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00429-014-0907-5","volume":"221","author":"Yao N.","year":"2016","unstructured":"Yao N.; Cheung C.; Pang S.; Multimodal MRI of the hippocampus in Parkinson\u2019s disease with visual hallucinations. Brain Struct Funct 2016,221(1),287-300","journal-title":"Brain Struct Funct"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.parkreldis.2014.02.001","volume":"20","author":"Monsell S.E.","year":"2014","unstructured":"Monsell S.E.; Besser L.M.; Heller K.B.; Checkoway H.; Litvan I.; Kukull W.A.; Clinical and pathologic presentation in Parkinson\u2019s disease by apolipoprotein e4 allele status. Parkinsonism Relat Disord 2014,20(5),503-507","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/00008571-200306000-00008","volume":"13","author":"Wang J.","year":"2003","unstructured":"Wang J.; Si Y-M.; Liu Z-L.; Yu L.; Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson\u2019s disease. Pharmacogenetics 2003,13(6),365-369","journal-title":"Pharmacogenetics"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1523\/JNEUROSCI.05-08-01972.1985","volume":"5","author":"Crawley J.N.","year":"1985","unstructured":"Crawley J.N.; Stivers J.A.; Blumstein L.K.; Paul S.M.; Cholecystokinin potentiates dopamine-mediated behaviors: Evidence for modulation specific to a site of coexistence. J Neurosci 1985,5(8),1972-1983","journal-title":"J Neurosci"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.neulet.2006.12.008","volume":"414","author":"Papapetropoulos S.","year":"2007","unstructured":"Papapetropoulos S.; Farrer M.J.; Stone J.T.; Phenotypic associations of tau and ApoE in Parkinson\u2019s disease. Neurosci Lett 2007,414(2),141-144","journal-title":"Neurosci Lett"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/mds.23806","volume":"26","author":"Factor S.A.","year":"2011","unstructured":"Factor S.A.; Steenland N.K.; Higgins D.S.; Disease-related and genetic correlates of psychotic symptoms in Parkinson\u2019s disease. Mov Disord 2011,26(12),2190-2195","journal-title":"Mov Disord"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/mds.20481","volume":"20","author":"Camicioli R.","year":"2005","unstructured":"Camicioli R.; Rajput A.; Rajput M.; Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson\u2019s disease: Relationship to dementia and hallucinations. Mov Disord 2005,20(8),989-994","journal-title":"Mov Disord"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/archneur.58.2.209","volume":"58","author":"Goetz C.G.","year":"2001","unstructured":"Goetz C.G.; Burke P.F.; Leurgans S.; Genetic variation analysis in parkinson disease patients with and without hallucinations: Case-control study. Arch Neurol 2001,58(2),209-213","journal-title":"Arch Neurol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.neulet.2003.11.006","volume":"355","author":"Wang J.","year":"2004","unstructured":"Wang J.; Zhao C.; Chen B.; Liu Z-L.; Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson\u2019s disease. Neurosci Lett 2004,355(3),193-196","journal-title":"Neurosci Lett"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1021\/cn500350e","volume":"6","author":"Puig M.V.","year":"2015","unstructured":"Puig M.V.; Gener T.; Serotonin modulation of prefronto-hippocampal rhythms in health and disease. ACS Chem Neurosci 2015,6(7),1017-1025","journal-title":"ACS Chem Neurosci"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/S0166-2236(96)10073-4","volume":"20","author":"Wonnacott S.","year":"1997","unstructured":"Wonnacott S.; Presynaptic nicotinic ACh receptors. Trends Neurosci 1997,20(2),92-98","journal-title":"Trends Neurosci"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"892459","DOI":"10.1155\/2013\/892459","volume":"2013","author":"Hoffmann M.","year":"2013","unstructured":"Hoffmann M.; The human frontal lobes and frontal network systems: An evolutionary, clinical, and treatment perspective. ISRN Neurol 2013,2013,892459","journal-title":"ISRN Neurol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.bbr.2010.11.037","volume":"221","author":"Drever B.D.","year":"2011","unstructured":"Drever B.D.; Riedel G.; Platt B.; The cholinergic system and hippocampal plasticity. Behav Brain Res 2011,221(2),505-514","journal-title":"Behav Brain Res"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.neuron.2007.03.006","volume":"54","author":"Couey J.J.","year":"2007","unstructured":"Couey J.J.; Meredith R.M.; Spijker S.; Distributed network actions by nicotine increase the threshold for spike-timing-dependent plasticity in prefrontal cortex. Neuron 2007,54(1),73-87","journal-title":"Neuron"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"176157","DOI":"10.1155\/2012\/176157","volume":"2012","author":"Kiernan J.A.","year":"2012","unstructured":"Kiernan J.A.; Anatomy of the temporal lobe. Epilepsy Res Treat 2012,2012,176157","journal-title":"Epilepsy Res Treat"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"10112","DOI":"10.1038\/s41598-017-10146-y","volume":"7","author":"Hepp D.H.","year":"2017","unstructured":"Hepp D.H.; Foncke E.M.J.; Berendse H.W.; Damaged fiber tracts of the nucleus basalis of Meynert in Parkinson\u2019s disease patients with visual hallucinations. Sci Rep 2017,7(1),10112","journal-title":"Sci Rep"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1006\/brcg.1995.1255","volume":"28","author":"Perry E.K.","year":"1995","unstructured":"Perry E.K.; Perry R.H.; Acetylcholine and hallucinations: Disease-related compared to drug-induced alterations in human consciousness. Brain Cogn 1995,28(3),240-258","journal-title":"Brain Cogn"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.bbr.2010.11.033","volume":"221","author":"Klinkenberg I.","year":"2011","unstructured":"Klinkenberg I.; Sambeth A.; Blokland A.; Acetylcholine and attention. Behav Brain Res 2011,221(2),430-442","journal-title":"Behav Brain Res"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1002\/mds.21077","volume":"21","author":"Burn D.","year":"2006","unstructured":"Burn D.; Emre M.; McKeith I.; Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson\u2019s disease. Mov Disord 2006,21(11),1899-1907","journal-title":"Mov Disord"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/pcn.12088","volume":"68","author":"Ogino S.","year":"2014","unstructured":"Ogino S.; Miyamoto S.; Miyake N.; Yamaguchi N.; Benefits and limits of anticholinergic use in schizophrenia: Focusing on its effect on cognitive function. Psychiatry Clin Neurosci 2014,68(1),37-49","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.tips.2008.06.006","volume":"29","author":"Geyer M.A.","year":"2008","unstructured":"Geyer M.A.; Vollenweider F.X.; Serotonin research: Contributions to understanding psychoses. Trends Pharmacol Sci 2008,29(9),445-453","journal-title":"Trends Pharmacol Sci"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3233\/JAD-150818","volume":"50","author":"Yasue I.","year":"2016","unstructured":"Yasue I.; Matsunaga S.; Kishi T.; Fujita K.; Iwata N.; Serotonin 2A Receptor inverse agonist as a treatment for Parkinson\u2019s disease psychosis: A systematic review and meta-analysis of serotonin 2A receptor negative modulators. J Alzheimers Dis 2016,50(3),733-740","journal-title":"J Alzheimers Dis"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3389\/fphar.2015.00225","volume":"6","author":"Zhang G.","year":"2015","unstructured":"Zhang G.; Stackman R.W.; The role of serotonin 5-HT2A receptors in memory and cognition. Front Pharmacol 2015,6,225","journal-title":"Front Pharmacol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1001\/archneurol.2010.35","volume":"67","author":"Ballanger B.","year":"2010","unstructured":"Ballanger B.; Strafella A.P.; van Eimeren T.; Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 2010,67(4),416-421","journal-title":"Arch Neurol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/mds.23083","volume":"25","author":"Huot P.","year":"2010","unstructured":"Huot P.; Johnston T.H.; Darr T.; Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord 2010,25(10),1399-1408","journal-title":"Mov Disord"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/j.1471-4159.2005.03485.x","volume":"95","author":"Bortolozzi A.","year":"2005","unstructured":"Bortolozzi A.; D\u00edaz-Mataix L.; Scorza M.C.; Celada P.; Artigas F.; The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J Neurochem 2005,95(6),1597-1607","journal-title":"J Neurochem"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuropharm.2013.10.021","volume":"79","author":"Mocci G.","year":"2014","unstructured":"Mocci G.; Jim\u00e9nez-S\u00e1nchez L.; Adell A.; Cort\u00e9s R.; Artigas F.; Expression of 5-HT2A receptors in prefrontal cortex pyramidal neurons projecting to nucleus accumbens. Potential relevance for atypical antipsychotic action. Neuropharmacology 2014,79,49-58","journal-title":"Neuropharmacology"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/schbul\/sbp006","volume":"35","author":"Howes O.D.","year":"2009","unstructured":"Howes O.D.; Kapur S.; The dopamine hypothesis of schizophrenia: Version III--the final common pathway. Schizophr Bull 2009,35(3),549-562","journal-title":"Schizophr Bull"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3389\/fpsyt.2013.00151","volume":"4","author":"Merritt K.","year":"2013","unstructured":"Merritt K.; McGuire P.; Egerton A.; Relationship between glutamate dysfunction and symptoms and cognitive function in psychosis. Front Psychiatry 2013,4,151","journal-title":"Front Psychiatry"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.euroneuro.2008.06.005","volume":"18","author":"Paz R.D.","year":"2008","unstructured":"Paz R.D.; Tardito S.; Atzori M.; Tseng K.Y.; Glutamatergic dysfunction in schizophrenia: From basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol 2008,18(11),773-786","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/j.1532-5415.1975.tb00187.x","volume":"23","author":"Postma J.U.","year":"1975","unstructured":"Postma J.U.; Van Tilburg W.; Visual hallucinations and delirium during treatment with amantadine (Symmetrel). J Am Geriatr Soc 1975,23(5),212-215","journal-title":"J Am Geriatr Soc"},{"key":"ref=129","first-page":"265","volume":"42","author":"Riederer P.","year":"1992","unstructured":"Riederer P.; Lange K.W.; Kornhuber J.; Danielczyk W.; Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia. Arzneimittelforschung 1992,42(2A),265-268","journal-title":"Arzneimittelforschung"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.parkreldis.2013.11.017","volume":"20","author":"Pagonabarraga J.","year":"2014","unstructured":"Pagonabarraga J.; Soriano-Mas C.; Llebaria G.; L\u00f3pez-Sol\u00e0 M.; Pujol J.; Kulisevsky J.; Neural correlates of minor hallucinations in non-demented patients with Parkinson\u2019s disease. Parkinsonism Relat Disord 2014,20(3),290-296","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/schbul\/sbx108","volume":"44","author":"Baglivo V.","year":"2018","unstructured":"Baglivo V.; Cao B.; Mwangi B.; Hippocampal subfield volumes in patients with first-episode psychosis. Schizophr Bull 2018,44(3),552-559","journal-title":"Schizophr Bull"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0920-9964(95)00028-K","volume":"17","author":"Bilder R.M.","year":"1995","unstructured":"Bilder R.M.; Bogerts B.; Ashtari M.; Anterior hippocampal volume reductions predict frontal lobe dysfunction in first episode schizophrenia. Schizophr Res 1995,17(1),47-58","journal-title":"Schizophr Res"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21767\/2171-6625.1000193","volume":"08","author":"Velasco M.","year":"2017","unstructured":"Velasco M.; Quintero J.R.; Castillo M.C.; Excitotoxicity: An organized crime at the cellular level. J Neurol Neurosci 2017,08(03),1-10","journal-title":"J Neurol Neurosci"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.parkreldis.2012.03.004","volume":"18","author":"Botha H.","year":"2012","unstructured":"Botha H.; Carr J.; Attention and visual dysfunction in Parkinson\u2019s disease. Parkinsonism Relat Disord 2012,18(6),742-747","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1212\/01.wnl.0000187116.13370.e0","volume":"65","author":"Oishi N.","year":"2005","unstructured":"Oishi N.; Udaka F.; Kameyama M.; Sawamoto N.; Hashikawa K.; Fukuyama H.; Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology 2005,65(11),1708-1715","journal-title":"Neurology"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/mds.20129","volume":"19","author":"Nagano-Saito A.","year":"2004","unstructured":"Nagano-Saito A.; Washimi Y.; Arahata Y.; Visual hallucination in Parkinson\u2019s disease with FDG PET. Mov Disord 2004,19(7),801-806","journal-title":"Mov Disord"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/hbm.22321","volume":"35","author":"Shine J.M.","year":"2014","unstructured":"Shine J.M.; Halliday G.M.; Gilat M.; The role of dysfunctional attentional control networks in visual misperceptions in Parkinson\u2019s disease. Hum Brain Mapp 2014,35(5),2206-2219","journal-title":"Hum Brain Mapp"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1093\/brain\/awr225","volume":"134","author":"Gallagher D.A.","year":"2011","unstructured":"Gallagher D.A.; Parkkinen L.; O\u2019Sullivan S.S.; Testing an aetiological model of visual hallucinations in Parkinson\u2019s disease. Brain 2011,134(Pt 11),3299-3309","journal-title":"Brain"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.parkreldis.2005.10.005","volume":"12","author":"Papapetropoulos S.","year":"2006","unstructured":"Papapetropoulos S.; McCorquodale D.S.; Gonzalez J.; Jean-Gilles L.; Mash D.C.; Cortical and amygdalar Lewy body burden in Parkinson\u2019s disease patients with visual hallucinations. Parkinsonism Relat Disord 2006,12(4),253-256","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/brain\/awf033","volume":"125","author":"Harding A.J.","year":"2002","unstructured":"Harding A.J.; Broe G.A.; Halliday G.M.; Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002,125(Pt 2),391-403","journal-title":"Brain"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"3682936","DOI":"10.1155\/2016\/3682936","volume":"2016","author":"Rasmussen N.B.","year":"2016","unstructured":"Rasmussen N.B.; Olesen M.V.; Brudek T.; 5-HT2A receptor binding in the frontal cortex of Parkinson\u2019s disease patients and alpha-synuclein overexpressing mice: a postmortem study. Park Dis 2016,2016,3682936","journal-title":"Park Dis"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.parkreldis.2014.06.018","volume":"20","author":"Jacobson S.A.","year":"2014","unstructured":"Jacobson S.A.; Morshed T.; Dugger B.N.; Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations. Parkinsonism Relat Disord 2014,20(9),1009-1014","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3389\/fnint.2012.00038","volume":"6","author":"Shomstein S.","year":"2012","unstructured":"Shomstein S.; Cognitive functions of the posterior parietal cortex: Top-down and bottom-up attentional control. Front Integr Nuerosci 2012,6,38","journal-title":"Front Integr Nuerosci"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1136\/jnnp.2009.179655","volume":"81","author":"Ibarretxe-Bilbao N.","year":"2010","unstructured":"Ibarretxe-Bilbao N.; Ramirez-Ruiz B.; Junque C.; Differential progression of brain atrophy in Parkinson\u2019s disease with and without visual hallucinations. J Neurol Neurosurg Psychiatry 2010,81(6),650-657","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/mds.22919","volume":"25","author":"Kurita A.","year":"2010","unstructured":"Kurita A.; Murakami M.; Takagi S.; Matsushima M.; Suzuki M.; Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies. Mov Disord 2010,25(2),167-171","journal-title":"Mov Disord"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1136\/jnnp.70.6.734","volume":"70","author":"Holroyd S.","year":"2001","unstructured":"Holroyd S.; Currie L.; Wooten G.F.; Prospective study of hallucinations and delusions in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 2001,70(6),734-738","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/brain\/123.4.733","volume":"123","author":"F\u00e9nelon G.","year":"2000","unstructured":"F\u00e9nelon G.; Mahieux F.; Huon R.; Zi\u00e9gler M.; Hallucinations in Parkinson\u2019s disease: Prevalence, phenomenology and risk factors. Brain 2000,123(Pt 4),733-745","journal-title":"Brain"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/mds.21382","volume":"22","author":"Ravina B.","year":"2007","unstructured":"Ravina B.; Marder K.; Fernandez H.H.; Diagnostic criteria for psychosis in Parkinson\u2019s disease: Report of an NINDS, NIMH work group. Mov Disord 2007,22(8),1061-1068","journal-title":"Mov Disord"},{"key":"ref=149","first-page":"289","volume":"21","author":"Diederich N.J.","year":"1998","unstructured":"Diederich N.J.; Goetz C.G.; Raman R.; Pappert E.J.; Leurgans S.; Piery V.; Poor visual discrimination and visual hallucinations in Parkinson\u2019s disease. Clin Neuropharmacol 1998,21(5),289-295","journal-title":"Clin Neuropharmacol"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1148\/radiol.2017170438","volume":"285","author":"Hepp D.H.","year":"2017","unstructured":"Hepp D.H.; Foncke E.M.J.; Olde Dubbelink K.T.E.; van de Berg W.D.J.; Berendse H.W.; Schoonheim M.M.; Loss of functional connectivity in patients with parkinson disease and visual hallucinations. Radiology 2017,285(3),896-903","journal-title":"Radiology"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jns.2017.06.011","volume":"379","author":"Lenka A.","year":"2017","unstructured":"Lenka A.; Herath P.; Christopher R.; Pal P.K.; Psychosis in Parkinson\u2019s disease: From the soft signs to the hard science. J Neurol Sci 2017,379,169-176","journal-title":"J Neurol Sci"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1093\/brain\/awt360","volume":"137","author":"Goldman J.G.","year":"2014","unstructured":"Goldman J.G.; Stebbins G.T.; Dinh V.; Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson\u2019s disease with hallucinations. Brain 2014,137(Pt 3),849-859","journal-title":"Brain"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1017\/S0140525X05000130","volume":"28","author":"Collerton D.","year":"2005","unstructured":"Collerton D.; Perry E.; McKeith I.; Why people see things that are not there: A novel Perception and Attention Deficit model for recurrent complex visual hallucinations. Behav Brain Sci 2005,28(6),737-757","journal-title":"Behav Brain Sci"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1212\/01.WNL.0000141853.27081.BD","volume":"63","author":"Stebbins G.T.","year":"2004","unstructured":"Stebbins G.T.; Goetz C.G.; Carrillo M.C.; Altered cortical visual processing in PD with hallucinations: An fMRI study. Neurology 2004,63(8),1409-1416","journal-title":"Neurology"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/mds.25543","volume":"29","author":"Lee J-Y.","year":"2014","unstructured":"Lee J-Y.; Kim J.M.; Ahn J.; Kim H-J.; Jeon B.S.; Kim T.W.; Retinal nerve fiber layer thickness and visual hallucinations in Parkinson\u2019s Disease. Mov Disord 2014,29(1),61-67","journal-title":"Mov Disord"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/mds.26533","volume":"31","author":"Lee J-Y.","year":"2016","unstructured":"Lee J-Y.; Yoon E.J.; Lee W.W.; Kim Y.K.; Lee J-Y.; Jeon B.; Lateral geniculate atrophy in Parkinson\u2019s with visual hallucination: A trans-synaptic degeneration? Mov Disord 2016,31(4),547-554","journal-title":"Mov Disord"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1176\/jnp.2006.18.3.402","volume":"18","author":"Holroyd S.","year":"2006","unstructured":"Holroyd S.; Wooten G.F.; Preliminary FMRI evidence of visual system dysfunction in Parkinson\u2019s disease patients with visual hallucinations. J Neuropsychiatry Clin Neurosci 2006,18(3),402-404","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1002\/mds.20582","volume":"20","author":"Pacchetti C.","year":"2005","unstructured":"Pacchetti C.; Manni R.; Zangaglia R.; Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson\u2019s disease. Mov Disord 2005,20(11),1439-1448","journal-title":"Mov Disord"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2165\/00002512-200825080-00004","volume":"25","author":"Zahodne L.B.","year":"2008","unstructured":"Zahodne L.B.; Fernandez H.H.; Pathophysiology and treatment of psychosis in Parkinson\u2019s disease: A review. Drugs Aging 2008,25(8),665-682","journal-title":"Drugs Aging"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.parkreldis.2017.07.011","volume":"43","author":"Barrett M.J.","year":"2017","unstructured":"Barrett M.J.; Smolkin M.E.; Flanigan J.L.; Shah B.B.; Harrison M.B.; Sperling S.A.; Characteristics, correlates, and assessment of psychosis in Parkinson disease without dementia. Parkinsonism Relat Disord 2017,43,56-60","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11818-016-0048-6","volume":"21","author":"H\u00f6gl B.","year":"2017","unstructured":"H\u00f6gl B.; Stefani A.; REM sleep behavior disorder (RBD): Update on diagnosis and treatment. Somnologie (Berl) 2017,21(S1),1-8","journal-title":"Somnologie (Berl)"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.concog.2010.10.009","volume":"20","author":"Manni R.","year":"2011","unstructured":"Manni R.; Terzaghi M.; Ratti P-L.; Repetto A.; Zangaglia R.; Pacchetti C.; Hallucinations and REM sleep behaviour disorder in Parkinson\u2019s disease: Dream imagery intrusions and other hypotheses. Conscious Cogn 2011,20(4),1021-1026","journal-title":"Conscious Cogn"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.sleep.2012.10.015","volume":"14","author":"Boeve B.F.","year":"2013","unstructured":"Boeve B.F.; Silber M.H.; Ferman T.J.; Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med 2013,14(8),754-762","journal-title":"Sleep Med"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/mds.26347","volume":"30","author":"Postuma R.B.","year":"2015","unstructured":"Postuma R.B.; Adler C.H.; Dugger B.N.; REM sleep behavior disorder and neuropathology in Parkinson\u2019s disease. Mov Disord 2015,30(10),1413-1417","journal-title":"Mov Disord"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"e89741","DOI":"10.1371\/journal.pone.0089741","volume":"9","author":"Iranzo A.","year":"2014","unstructured":"Iranzo A.; Fern\u00e1ndez-Arcos A.; Tolosa E.; Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: Study in 174 patients. PLoS One 2014,9(2),e89741","journal-title":"PLoS One"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.cortex.2015.10.015","volume":"74","author":"Geddes M.R.","year":"2016","unstructured":"Geddes M.R.; Tie Y.; Gabrieli J.D.E.; McGinnis S.M.; Golby A.J.; Whitfield-Gabrieli S.; Altered functional connectivity in lesional peduncular hallucinosis with REM sleep behavior disorder. Cortex J Devoted Study Nerv Syst Behav 2016,74,96-106","journal-title":"Cortex J Devoted Study Nerv Syst Behav"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.parkreldis.2015.11.018","volume":"22","author":"Lenka A.","year":"2016","unstructured":"Lenka A.; Hegde S.; Jhunjhunwala K.R.; Pal P.K.; Interactions of visual hallucinations, rapid eye movement sleep behavior disorder and cognitive impairment in Parkinson\u2019s disease: A review. Parkinsonism Relat Disord 2016,22,1-8","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.amjopharm.2010.08.002","volume":"8","author":"Wood L.D.","year":"2010","unstructured":"Wood L.D.; Neumiller J.J.; Setter S.M.; Dobbins E.K.; Clinical review of treatment options for select nonmotor symptoms of Parkinson\u2019s disease. Am J Geriatr Pharmacother 2010,8(4),294-315","journal-title":"Am J Geriatr Pharmacother"},{"key":"ref=169","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/09540260020002541","volume":"12","author":"Henderson M.J.","year":"2009","unstructured":"Henderson M.J.; Mellers J.D.C.; Psychosis in Parkinson\u2019s disease: \u2018between a rock and a hard place. Int Rev Psychiatry 2009,12(4),319","journal-title":"Int Rev Psychiatry"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/mds.20260","volume":"20","author":"Fernandez H.H.","year":"2005","unstructured":"Fernandez H.H.; Trieschmann M.E.; Okun M.S.; Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson\u2019s disease. Mov Disord 2005,20(1),104-105","journal-title":"Mov Disord"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"CD009922","DOI":"10.1002\/14651858.CD009922.pub2","volume":"4","author":"Du M.","year":"2017","unstructured":"Du M.; Wang X.; Yin S.; De-escalation techniques for psychosis-induced aggression or agitation. Cochrane Database Syst Rev 2017,4(4),CD009922","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"R73","DOI":"10.1186\/cc11330","volume":"16","author":"Van Rompaey B.","year":"2012","unstructured":"Van Rompaey B.; Elseviers M.M.; Van Drom W.; Fromont V.; Jorens P.G.; The effect of earplugs during the night on the onset of delirium and sleep perception: A randomized controlled trial in intensive care patients. Crit Care 2012,16(3),R73","journal-title":"Crit Care"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/anae.12638","volume":"69","author":"Patel J.","year":"2014","unstructured":"Patel J.; Baldwin J.; Bunting P.; Laha S.; The effect of a multicomponent multidisciplinary bundle of interventions on sleep and delirium in medical and surgical intensive care patients. Anaesthesia 2014,69(6),540-549","journal-title":"Anaesthesia"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1136\/bmj.322.7279.144","volume":"322","author":"Meagher D.J.","year":"2001","unstructured":"Meagher D.J.; Delirium: Optimising management. BMJ 2001,322(7279),144-149","journal-title":"BMJ"},{"key":"ref=175","first-page":"266","volume":"27","author":"Black K.J.","year":"2017","unstructured":"Black K.J.; Treatment of Parkinson\u2019s disease psychosis. Med Int Rev 2017,27(109),266-271","journal-title":"Med Int Rev"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3988\/jcn.2012.8.1.15","volume":"8","author":"Shin H-W.","year":"2012","unstructured":"Shin H-W.; Chung S.J.; Drug-induced parkinsonism. J Clin Neurol 2012,8(1),15-21","journal-title":"J Clin Neurol"},{"key":"ref=177","author":"Haidary H.A.","year":"2021","unstructured":"Haidary H.A.; Padhy R.K.; Clozapine. StatPearls [Internet] Available from: 2021","journal-title":"StatPearls [Internet]"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"E2087","DOI":"10.3390\/molecules23082087","volume":"23","author":"Haidary H.A.","year":"2018","unstructured":"Haidary H.A.; St\u0119pnicki P; Kondej M; Kaczor AA; Current concepts and treatments of schizophrenia. Molecules 2018,23(8),E2087","journal-title":"Molecules"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","volume":"75","author":"Pollak P.","year":"2004","unstructured":"Pollak P.; Tison F.; Rascol O.; Clozapine in drug induced psychosis in Parkinson\u2019s disease: A randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004,75(5),689-695","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.2147\/NDT.S201029","volume":"15","author":"Zhang H.","year":"2019","unstructured":"Zhang H.; Wang L.; Fan Y.; Atypical antipsychotics for Parkinson\u2019s disease psychosis: A systematic review and meta-analysis. Neuropsychiatr Dis Treat 2019,15,2137-2149","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/01.wnf.0000136891.17006.ec","volume":"27","author":"Morgante L.","year":"2004","unstructured":"Morgante L.; Epifanio A.; Spina E.; Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004,27(4),153-156","journal-title":"Clin Neuropharmacol"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/01.WNF.0000236769.31279.19","volume":"29","author":"Merims D.","year":"2006","unstructured":"Merims D.; Balas M.; Peretz C.; Shabtai H.; Giladi N.; Rater-blinded, prospective comparison: Quetiapine versus clozapine for Parkinson\u2019s disease psychosis. Clin Neuropharmacol 2006,29(6),331-337","journal-title":"Clin Neuropharmacol"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/NDT.S5335","volume":"5","author":"Shotbolt P.","year":"2009","unstructured":"Shotbolt P.; Samuel M.; Fox C.; David A.S.; A randomized controlled trial of quetiapine for psychosis in Parkinson\u2019s disease. Neuropsychiatr Dis Treat 2009,5,327-332","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"150","DOI":"10.12688\/f1000research.2-150.v1","volume":"2","author":"Nichols M.J.","year":"2013","unstructured":"Nichols M.J.; Hartlein J.M.; Eicken M.G.; Racette B.A.; Black K.J.; A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease. F1000 Res 2013,2,150","journal-title":"F1000 Res"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"262","DOI":"10.9740\/mhc.2017.11.262","volume":"7","author":"Chen J.J.","year":"2018","unstructured":"Chen J.J.; Treatment of psychotic symptoms in patients with Parkinson disease. Ment Health Clin 2018,7(6),262-270","journal-title":"Ment Health Clin"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/WNF.0b013e31824d5115","volume":"35","author":"Pintor L.","year":"2012","unstructured":"Pintor L.; Valldeoriola F.; Baill\u00e9s E.; Mart\u00ed M.J.; Mu\u00f1iz A.; Tolosa E.; Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: A randomized open clinical trial. Clin Neuropharmacol 2012,35(2),61-66","journal-title":"Clin Neuropharmacol"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/mds.10217","volume":"17","author":"Ondo W.G.","year":"2002","unstructured":"Ondo W.G.; Levy J.K.; Vuong K.D.; Hunter C.; Jankovic J.; Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002,17(5),1031-1035","journal-title":"Mov Disord"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0006-3223(02)01392-6","volume":"52","author":"Breier A.","year":"2002","unstructured":"Breier A.; Sutton V.K.; Feldman P.D.; Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson\u2019s disease. Biol Psychiatry 2002,52(5),438-445","journal-title":"Biol Psychiatry"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/mds.870120423","volume":"12","author":"Meco G.","year":"1997","unstructured":"Meco G.; Alessandri A.; Giustini P.; Bonifati V.; Risperidone in levodopa-induced psychosis in advanced Parkinson\u2019s disease: An open-label, long-term study. Mov Disord 1997,12(4),610-612","journal-title":"Mov Disord"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1176\/jnp.12.3.364","volume":"12","author":"Ellis T.","year":"2000","unstructured":"Ellis T.; Cudkowicz M.E.; Sexton P.M.; Growdon J.H.; Clozapine and risperidone treatment of psychosis in Parkinson\u2019s disease. J Neuropsychiatry Clin Neurosci 2000,12(3),364-369","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9","volume":"15","author":"Mohr E.","year":"2000","unstructured":"Mohr E.; Mendis T.; Hildebrand K.; De Deyn P.P.; Risperidone in the treatment of dopamine-induced psychosis in Parkinson\u2019s disease: An open pilot trial. Mov Disord 2000,15(6),1230-1237","journal-title":"Mov Disord"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1517\/14656560802532707","volume":"9","author":"Abbas A.","year":"2008","unstructured":"Abbas A.; Roth B.L.; Pimavanserin tartrate: A 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin Pharmacother 2008,9(18),3251-3259","journal-title":"Expert Opin Pharmacother"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1124\/jpet.105.097006","volume":"317","author":"Vanover K.E.","year":"2006","unstructured":"Vanover K.E.; Weiner D.M.; Makhay M.; Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 2006,317(2),910-918","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1002\/mds.27488","volume":"33","author":"Espay A.J.","year":"2018","unstructured":"Espay A.J.; Guskey M.T.; Norton J.C.; Pimavanserin for Parkinson\u2019s Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. Mov Disord 2018,33(11),1769-1776","journal-title":"Mov Disord"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/npp.2009.176","volume":"35","author":"Meltzer H.Y.","year":"2010","unstructured":"Meltzer H.Y.; Mills R.; Revell S.; Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson\u2019s disease psychosis. Neuropsychopharmacology 2010,35(4),881-892","journal-title":"Neuropsychopharmacology"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"Cummings J.","year":"2014","unstructured":"Cummings J.; Isaacson S.; Mills R.; Pimavanserin for patients with Parkinson\u2019s disease psychosis: A randomised, placebo-controlled phase 3 trial. Lancet 2014,383(9916),533-540","journal-title":"Lancet"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5498\/wjp.v9.i3.47","volume":"9","author":"Tampi R.R.","year":"2019","unstructured":"Tampi R.R.; Tampi D.J.; Young J.J.; Balachandran S.; Hoq R.A.; Manikkara G.; Evidence for using pimavanserin for the treatment of Parkinson\u2019s disease psychosis. World J Psychiatry 2019,9(3),47-54","journal-title":"World J Psychiatry"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.119.260281","volume":"371","author":"Dedic N.","year":"2019","unstructured":"Dedic N.; Jones P.G.; Hopkins S.C.; SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action. J Pharmacol Exp Ther 2019,371(1),1-14","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.3233\/JPD-202103","volume":"10","author":"Savitt J.","year":"2020","unstructured":"Savitt J.; Aouchiche R.; Management of visual dysfunction in patients with Parkinson\u2019s disease. J Parkinsons Dis 2020,10(s1),S49-S56","journal-title":"J Parkinsons Dis"},{"key":"ref=200","unstructured":"Sunovion. A study to evaluate the efficacy, safety and tolerability of SEP-363856 in subjects with Parkinson\u2019s disease psychosis. Report No.: NCT02969369. Available from:"},{"key":"ref=201","unstructured":"SRC inhibition as a potential target for Parkinson\u2019s disease psychosis (SCRIPT). Report No.: NCT03661125. King\u2019s College LondonAvailable from:"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/0269881108096519","volume":"23","author":"Zuardi A.W.","year":"2009","unstructured":"Zuardi A.W.; Crippa J.A.; Hallak J.E.; Cannabidiol for the treatment of psychosis in Parkinson\u2019s disease. J Psychopharmacol 2009,23(8),979-983","journal-title":"J Psychopharmacol"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"2045125319881916","DOI":"10.1177\/2045125319881916","volume":"9","author":"Davies C.","year":"2019","unstructured":"Davies C.; Bhattacharyya S.; Cannabidiol as a potential treatment for psychosis. Ther Adv Psychopharmacol 2019,9,2045125319881916","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.euroneuro.2013.11.002","volume":"24","author":"Schubart C.D.","year":"2014","unstructured":"Schubart C.D.; Sommer I.E.C.; Fusar-Poli P.; de Witte L.; Kahn R.S.; Boks M.P.M.; Cannabidiol as a potential treatment for psychosis. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 2014,24(1),51-64","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ejphar.2005.02.040","volume":"512","author":"Moreira F.A.","year":"2005","unstructured":"Moreira F.A.; Guimar\u00e3es F.S.; Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol 2005,512(2-3),199-205","journal-title":"Eur J Pharmacol"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2125.2012.04341.x","volume":"75","author":"Fern\u00e1ndez-Ruiz J.","year":"2013","unstructured":"Fern\u00e1ndez-Ruiz J.; Sagredo O.; Pazos M.R.; Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol 2013,75(2),323-333","journal-title":"Br J Clin Pharmacol"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881114550355","volume":"28","author":"Chagas M.H.N.","year":"2014","unstructured":"Chagas M.H.N.; Zuardi A.W.; Tumas V.; Effects of cannabidiol in the treatment of patients with Parkinson\u2019s disease: An exploratory double-blind trial. J Psychopharmacol 2014,28(11),1088-1098","journal-title":"J Psychopharmacol"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00001756-199702100-00014","volume":"8","author":"French E.D.","year":"1997","unstructured":"French E.D.; Dillon K.; Wu X.; Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 1997,8(3),649-652","journal-title":"Neuroreport"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1111\/j.1460-9568.1998.00292.x","volume":"10","author":"Diana M.","year":"1998","unstructured":"Diana M.; Melis M.; Gessa G.L.; Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. Eur J Neurosci 1998,10(9),2825-2830","journal-title":"Eur J Neurosci"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/BF02244189","volume":"104","author":"Zuardi A.W.","year":"1991","unstructured":"Zuardi A.W.; Rodrigues J.A.; Cunha J.M.; Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl) 1991,104(2),260-264","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1136\/jnnp-2014-308764","volume":"86","author":"Pagano G.","year":"2015","unstructured":"Pagano G.; Rengo G.; Pasqualetti G.; Cholinesterase inhibitors for Parkinson\u2019s disease: A systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2015,86(7),767-773","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/gps.993","volume":"19","author":"Leroi I.","year":"2004","unstructured":"Leroi I.; Brandt J.; Reich S.G.; Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson\u2019s disease. Int J Geriatr Psychiatry 2004,19(1),1-8","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s100720200022","volume":"23","author":"Fabbrini G.","year":"2002","unstructured":"Fabbrini G.; Barbanti P.; Aurilia C.; Pauletti C.; Lenzi G.L.; Meco G.; Donepezil in the treatment of hallucinations and delusions in Parkinson\u2019s disease. Neurol Sci 2002,23(1),41-43","journal-title":"Neurol Sci"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/mds.1204","volume":"16","author":"Reading P.J.","year":"2001","unstructured":"Reading P.J.; Luce A.K.; McKeith I.G.; Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial. Mov Disord 2001,16(6),1171-1174","journal-title":"Mov Disord"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/00002826-200211000-00002","volume":"25","author":"Richard I.H.","year":"2002","unstructured":"Richard I.H.; Justus A.W.; Greig N.H.; Marshall F.; Kurlan R.; Worsening of motor function and mood in a patient with Parkinson\u2019s disease after pharmacologic challenge with oral rivastigmine. Clin Neuropharmacol 2002,25(6),296-299","journal-title":"Clin Neuropharmacol"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/pcn.12175","volume":"68","author":"Tsai C-H.","year":"2014","unstructured":"Tsai C-H.; Huang H-C.; Liu B-L.; Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of Parkinson\u2019s disease with dementia. Psychiatry Clin Neurosci 2014,68(9),692-700","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/1531-8257(200011)15:6<1225::AID-MDS1025>3.0.CO;2-A","volume":"15","author":"Di Rocco A.","year":"2000","unstructured":"Di Rocco A.; Rogers J.D.; Brown R.; Werner P.; Bottiglieri T.; S-Adenosyl-Methionine improves depression in patients with Parkinson\u2019s disease in an open-label clinical trial. Mov Disord 2000,15(6),1225-1229","journal-title":"Mov Disord"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.euroneuro.2008.08.004","volume":"19","author":"Strous R.D.","year":"2009","unstructured":"Strous R.D.; Ritsner M.S.; Adler S.; Improvement of aggressive behavior and quality of life impairment following S-adenosyl-methionine (SAM-e) augmentation in schizophrenia. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 2009,19(1),14-22","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/psb.804","volume":"22","author":"Spencer R.","year":"2011","unstructured":"Spencer R.; Serumaga B.; Prescribing antiemetics for patients with Parkinson\u2019s. Prescriber 2011,22(18),48-49","journal-title":"Prescriber"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/0140-6736(93)90327-D","volume":"341","author":"Zoldan J.","year":"1993","unstructured":"Zoldan J.; Friedberg G.; Goldberg-Stern H.; Melamed E.; Ondansetron for hallucinosis in advanced Parkinson\u2019s disease. Lancet 1993,341(8844),562-563","journal-title":"Lancet"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1212\/WNL.45.7.1305","volume":"45","author":"Zoldan J.","year":"1995","unstructured":"Zoldan J.; Friedberg G.; Livneh M.; Melamed E.; Psychosis in advanced Parkinson\u2019s disease: Treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995,45(7),1305-1308","journal-title":"Neurology"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1212\/WNL.47.6.1608-b","volume":"47","author":"Eichhorn T.E.","year":"1996","unstructured":"Eichhorn T.E.; Brunt E.; Oertel W.H.; Ondansetron treatment of L-dopa-induced psychosis. Neurology 1996,47(6),1608-1609","journal-title":"Neurology"},{"key":"ref=223","first-page":"200","volume":"30","author":"Tampi R.R.","year":"2018","unstructured":"Tampi R.R.; Maksimowski M.; Lingamchetty T.; Farheen S.A.; Is ondansetron beneficial for psychosis associated with dementia? Ann Clin Psychiatry 2018,30(3),200-206","journal-title":"Ann Clin Psychiatry"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"156","DOI":"10.4103\/0019-5545.82549","volume":"53","author":"Muralidharan K.","year":"2011","unstructured":"Muralidharan K.; Thimmaiah R.; Chakraborty V.; Jain S.; Bifrontal ECT for drug-induced psychosis in Parkinson\u2019s disease. Indian J Psychiatry 2011,53(2),156-158","journal-title":"Indian J Psychiatry"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/YCT.0b013e3181c18a3d","volume":"26","author":"Ueda S.","year":"2010","unstructured":"Ueda S.; Koyama K.; Okubo Y.; Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. J ECT 2010,26(2),111-115","journal-title":"J ECT"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.pnpbp.2011.05.003","volume":"35","author":"Usui C.","year":"2011","unstructured":"Usui C.; Hatta K.; Doi N.; Improvements in both psychosis and motor signs in Parkinson\u2019s disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiatry 2011,35(7),1704-1708","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/YCT.0000000000000138","volume":"30","author":"Baldinger P.","year":"2014","unstructured":"Baldinger P.; Lotan A.; Frey R.; Kasper S.; Lerer B.; Lanzenberger R.; Neurotransmitters and electroconvulsive therapy. J ECT 2014,30(2),116-121","journal-title":"J ECT"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.mehy.2009.06.053","volume":"73","author":"Popeo D.","year":"2009","unstructured":"Popeo D.; Kellner C.H.; ECT for Parkinson\u2019s disease. Med Hypotheses 2009,73(4),468-469","journal-title":"Med Hypotheses"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1176\/jnp.15.4.407","volume":"15","author":"Kennedy R.","year":"2003","unstructured":"Kennedy R.; Mittal D.; O\u2019Jile J.; Electroconvulsive therapy in movement disorders: An update. J Neuropsychiatry Clin Neurosci 2003,15(4),407-421","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1590\/0004-282X20150131","volume":"73","author":"Calder\u00f3n-Fajardo H.","year":"2015","unstructured":"Calder\u00f3n-Fajardo H.; Cervantes-Arriaga A.; Llorens-Arenas R.; Ram\u00edrez-Bermudez J.; Ruiz-Chow \u00c1.; Rodr\u00edguez-Violante M.; Electroconvulsive therapy in Parkinson\u2019s disease. Arq Neuropsiquiatr 2015,73(10),856-860","journal-title":"Arq Neuropsiquiatr"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1097\/YCT.0b013e3182611563","volume":"29","author":"Sadananda S.K.","year":"2013","unstructured":"Sadananda S.K.; Holla B.; Viswanath B.; Effectiveness of electroconvulsive therapy for drug-induced parkinsonism in the elderly. J ECT 2013,29(1),e6-e7","journal-title":"J ECT"},{"key":"ref=232","first-page":"1405","volume":"121","author":"Nishioka K","year":"2014","unstructured":"Nishioka K; Tanaka R; Shimura H; Hirano K; Hatano T; Miyakawa K; Quantitative evaluation of electroconvulsive therapy for Parkinson\u2019s disease with refractory psychiatric symptoms. J Neural Transm Vienna Austria 1996 2014,121(11),1405","journal-title":"J Neural Transm Vienna Austria 1996"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1212\/WNL.0000000000003279","volume":"87","author":"Brys M.","year":"2016","unstructured":"Brys M.; Fox M.D.; Agarwal S.; Multifocal repetitive TMS for motor and mood symptoms of Parkinson disease: A randomized trial. Neurology 2016,87(18),1907-1915","journal-title":"Neurology"},{"key":"ref=234","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/bs.irn.2017.05.009","volume":"134","author":"Rektorov\u00e1 I.","year":"2017","unstructured":"Rektorov\u00e1 I.; Anderkov\u00e1 \u013d.; Noninvasive brain stimulation and implications for nonmotor symptoms in Parkinson\u2019s disease. Int Rev Neurobiol 2017,134,1091-1110","journal-title":"Int Rev Neurobiol"},{"key":"ref=235","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1001\/jamapsychiatry.2015.3127","volume":"73","author":"Camprodon J.A.","year":"2016","unstructured":"Camprodon J.A.; Pascual-Leone A.; Multimodal applications of transcranial magnetic stimulation for circuit-based psychiatry. JAMA Psychiatry 2016,73(4),407-408","journal-title":"JAMA Psychiatry"},{"key":"ref=236","doi-asserted-by":"publisher","first-page":"e3561","DOI":"10.17795\/ijpbs-3561","volume":"10","author":"Ghanbari Jolfaei A.","year":"2016","unstructured":"Ghanbari Jolfaei A.; Naji B.; Nasr Esfehani M.; Repetitive transcranial magnetic stimulation in resistant visual hallucinations in a woman with schizophrenia: A case report. Iran J Psychiatry Behav Sci 2016,10(1),e3561","journal-title":"Iran J Psychiatry Behav Sci"},{"key":"ref=237","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1159\/000325102","volume":"44","author":"Blom J.D.","year":"2011","unstructured":"Blom J.D.; Looijestijn J.; Goekoop R.; Treatment of Alice in wonderland syndrome and verbal auditory hallucinations using repetitive transcranial magnetic stimulation: a case report with fmri findings. Psychopathology 2011,44(5),337-344","journal-title":"Psychopathology"},{"key":"ref=238","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jocn.2019.08.002","volume":"69","author":"Hano\u011flu T","year":"2019","unstructured":"Hano\u011flu T; Hano\u011flu L; G\u00fcntekin B; Akt\u00fcrk T; Yulug B; The therapeutic role of repetitive transcranial magnetic stimulation (rTMS) in parkinsonian visual hallucinations: Electrophysiological correlates. J Clin Neurosci 2019,69,281-284","journal-title":"J Clin Neurosci"},{"key":"ref=239","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13195-018-0465-9","volume":"11","author":"Elder G.J.","year":"2019","unstructured":"Elder G.J.; Colloby S.J.; Firbank M.J.; McKeith I.G.; Taylor J-P.; Consecutive sessions of transcranial direct current stimulation do not remediate visual hallucinations in Lewy body dementia: A randomised controlled trial. Alzheimers Res Ther 2019,11(1),9","journal-title":"Alzheimers Res Ther"},{"key":"ref=240","unstructured":"The INSYTE (management of Parkinson\u2019s Disease Psychosis in Actual Practice) Study. Report No.: NCT03152292. ACADIA Pharmaceuticals IncAvailable from:"},{"key":"ref=241","unstructured":"Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson\u2019s Disease Psychosis Report No: NCT04292223 ACADIA Pharmaceuticals IncAvailable from:","journal-title":"Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson\u2019s Disease Psychosis Report No: NCT04292223"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612828666220428102802","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/204173\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612828666220428102802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T09:22:22Z","timestamp":1691745742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/204173\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":241,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612828666220428102802","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-12-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}